actin binding is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-04. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
| Property | Value | Notes |
|---|---|---|
| Storage temperature (dry) | -20 °C | Protected from light and moisture |
| Storage temperature (solution) | -80 °C | Single-use aliquots recommended |
| Identity assay | LC-MS or MALDI-TOF | Confirms mass near 889 Da |
| Purity assay | RP-HPLC | Reports main peak percentage |
| Common impurities | Truncated peptides, deamidated forms | Arise from synthesis or storage |
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
== Historical note == An. gambiae invaded northeastern Brazil in 1930, which led to a malaria epidemic in 1938/1939. The Brazilian government assisted by the Rockefeller Foundation in a programme spearheaded by Fred Soper eradicated these mosquitoes from this area. This effort was modeled on the earlier success in eradication of Aedes aegypti as part of the yellow fever control program. The exact species involved in this epidemic has been identified as An. arabiensis.
Albert Ladenburg investigated the reactions of pyridine and the preparation of its derivatives. In 1899, he published the reaction of pyridine with iodoethane at 290 °C in a sealed ampoule, in which he obtained, among other products, 4-ethylpyridine. A key figure in pyridine research was Alexei Yevgenyevich Chichibabin. He first prepared 2-benzylpyridine and 4-benzylpyridine by alkylating pyridine with benzyl halides at high temperatures. He also prepared 3-benzylpyridine by reducing 3-benzoylpyridine with hydroiodic acid. A milestone in this field was the development of the Chichibabin pyridine synthesis named after him, which he first published around 1905. In this reaction, the pyridine ring is constructed from ammonia and aldehydes; depending on the aldehydes used, various substituted derivatives can be obtained. With the Chichibabin reaction, also named after him and first published in 1914, pyridine can be reacted with sodium amide to give 2-aminopyridine as well as pyridine derivatives analogous to 2-amino compounds. The biological significance of pyridines was discovered in the 1930s. This included the function of nicotinamide adenine dinucleotide (NAD) and its phosphate (nicotinamide adenine dinucleotide phosphate) as carriers of hydrogen atoms in biological systems. It was also discovered at that time that a deficiency of nicotinic acid (vitamin B3, the precursor of NAD and NADP) was responsible for the disease pellagra. This disease was widespread at the time, for example in the southern states of the USA.
==== Operation Sem Desconto ==== On 23 April 2025, the Federal Police (PF) and the Comptroller General of the Union (CGU) launched Operation Sem Desconto, to combat a criminal scheme that, since 2019, had been promoting the diversion of more than 6.3 billion reais from retirement and pension payments made by the National Institute of Social Security (INSS), by using entities constituted solely for the purpose of including payroll deductions directly in the payment of their benefits, without the beneficiary's authorization. The legal authorization for deduction of association dues directly from payments to retirees and pensioners has existed since 1991. According to the CGU and the Ministry of Justice and Public Security, class entities, such as associations and unions, formalized Technical Cooperation Agreements (ACT) with the INSS, which justified payroll deductions from the agency's beneficiaries. However, the authorization for the deductions was, in many cases, forged. In this way, the CGU began a series of investigations after identifying the surge in the collection of the entities and in the deducted amounts from 2023 onward. Among the reasons for the increase in deductions are the loosening of rules, motivated by lobbies in the National Congress, failures by the INSS in control and oversight, and political appointments to the agency.
== Recent work on homing peptides and nanomedicine == Ruoslahti's research group has developed a novel class of tumor-homing peptides that can be used to enhance delivery of drugs and nanoparticles to tumors. These tumor-penetrating peptides selectively home to tumor vessels, where they activate a transport pathway that delivers the peptide, and along with it drugs and even nanoparticles, through the wall of tumor blood vessels and deep into tumor tissue. Having bound to tumor vessels the peptide is cleaved and an amino acid sequence motif named the C-end rule or CendR motif (pronounced "sender") is exposed at the C-terminus of the peptide. Subsequent binding of the peptide to neuropilin-1 activates the CendR transport pathway into and through tumor tissue. The prototype tumor-penetrating peptide, iRGD, is in clinical trials in solid tumor patients tested as an enhancer of cancer therapies. This peptide recognizes many different types of cancers, and it can be used for tumor delivery of various payloads that are either coupled to the peptide, or given together with it. iRGD has also been shown to effectively deliver drugs to the placenta, which could aid in the treatment of slow fetal growth. Recently, in vivo phage screening has been used to identify peptides that target hypertensive pulmonary arteries, atherosclerosis, and diseases of the brain.
==== Distribution ==== The brain tissue distribution of muscimol in rats has been studied. Muscimol rapidly enters and unevenly distributes in rat brain, especially in the substantia nigra, colliculi, and hypothalamus. Muscimol crosses the blood–brain barrier and hence is centrally active. This has been said to likely be mediated by active transport via the high-affinity GABA uptake system and other amino acid transporters. Although muscimol crosses the blood–brain barrier, it does so relatively poorly and far less readily than gaboxadol.
Sources: en.wikipedia.org
The A form occurs under non-physiological conditions in partly dehydrated samples of DNA, while in the cell it may be produced in hybrid pairings of DNA and RNA strands, and in enzyme-DNA complexes. Segments of DNA where the bases have been chemically modified by methylation may undergo a larger change in conformation and adopt the Z form. Here, the strands turn about the helical axis in a left-handed spiral, the opposite of the more common B form. These unusual structures can be recognized by specific Z-DNA binding proteins and may be involved in the regulation of transcription.
Bioinformatics (or "gold biotechnology") is an interdisciplinary field that addresses biological problems using computational techniques, and makes the rapid organization as well as analysis of biological data possible. The field may also be referred to as computational biology, and can be defined as, "conceptualizing biology in terms of molecules and then applying informatics techniques to understand and organize the information associated with these molecules, on a large scale". Bioinformatics plays a key role in various areas, such as functional genomics, structural genomics, and proteomics, and forms a key component in the biotechnology and pharmaceutical sector. Blue biotechnology is based on the exploitation of sea resources to create products and industrial applications. This branch of biotechnology is the most used for the industries of refining and combustion principally on the production of bio-oils with photosynthetic micro-algae. Green biotechnology is biotechnology applied to agricultural processes. An example would be the selection and domestication of plants via micropropagation. Another example is the designing of transgenic plants to grow under specific environments in the presence (or absence) of chemicals. One hope is that green biotechnology might produce more environmentally friendly solutions than traditional industrial agriculture. An example of this is the engineering of a plant to express a pesticide, thereby ending the need of external application of pesticides. An example of this would be Bt corn.
A survival store is a retail outlet where outdoor survival or preparedness equipment can be purchased. Typically survival stores stock camping and backpacking equipment, long-term storage food, fishing equipment, and occasionally bicycles.
Latent autoimmune diabetes in adults (LADA) is an autoimmune disease with gradual or slow destruction of pancreatic beta cells (β-cells). It is a form of type 1 diabetes (T1D) that manifests in adulthood, rather than childhood or adolescence. Due to the adult onset of LADA, as well as the relative preservation of insulin secretion at diagnosis and its slower rate of progression compared to classic T1D, LADA is often misdiagnosed as type 2 diabetes mellitus (T2D) which is a metabolic disorder rather than an autoimmune disease. The concept of LADA was first introduced in 1993. Though sometimes colloquially referred to as "type 1.5 diabetes" due to its sharing some clinical and metabolic characteristics of both T1D and T2D, LADA is strictly defined under the rubric of T1D by the American Diabetes Association (ADA) as an autoimmune form of diabetes. Most individuals with LADA have circulating islet autoantibodies which are indicative of progressive β-cell loss and may help predict the rate of disease progression. Misdiagnosis of LADA can lead to inappropriate treatment, as patients may be managed as having T2D rather than their underlying autoimmune condition.
Sources: en.wikipedia.org
The dry powder is normally kept at -20 °C, protected from light and moisture. Reconstituted solutions are often divided into aliquots and stored at -80 °C to reduce freeze-thaw damage.
Reverse-phase HPLC assesses purity, and mass spectrometry confirms molecular mass. The combination helps distinguish the target peptide from truncated or modified impurities.
Buffer composition, pH, adsorption to containers, and freeze-thaw history can all affect the amount of intact peptide in solution. These factors may change results even when the starting material is chemically correct.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.